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Abstract
Patients infected with the hepatitis C virus (HCV) are 
characterized by a high incidence of chronic infection, 
which results in chronic hepatitis, liver cirrhosis, and 
hepatocellular carcinoma. The functional impairment 
of HCV-specific T cells is associated with the evolution 
of an acute infection to chronic hepatitis. While T cells 
are the important effector cells in adaptive immunity, 
natural killer (NK) cells are the critical effector cells 
in innate immunity to virus infections. The findings of 
recent studies on NK cells in hepatitis C suggest that NK 
cell responses are indeed important in each phase of 
HCV infection. In the early phase, NK cells are involved 
in protective immunity to HCV. The immune evasion 
strategies used by HCV may target NK cells and might 
contribute to the progression to chronic hepatitis C. NK 
cells may control HCV replication and modulate hepatic 
fibrosis in the chronic phase. Further investigations 
are, however, needed, because a considerable number 
of studies observed functional impairment of NK cells 
in chronic HCV infection. Interestingly, the enhanced 
NK cell responses during interferon-α-based therapy 
of chronic hepatitis C indicate successful treatment. 
In spite of the advances in research on NK cells in 
hepatitis C, establishment of more physiological HCV 
infection model systems is needed to settle unsolved 
controversies over the role and functional status of NK 
cells in HCV infection.
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Core tip: Natural killer (NK) cells protect our body from 
viral infections by killing infected cells and secreting 
cytokines that inhibit viral replication. Unlike T 
lymphocytes that require priming by antigen presenting 
cells, NK cells directly recognize virus-infected cells 
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and immediately exert antiviral effector functions. 
Researchers who investigate immunity to hepatitis C 
virus (HCV), therefore, have been interested in NK cells. 
This review will give readers an overview of reports 
on NK cells in hepatitis C and insights into the role 
of NK cells in the defense against HCV infection, the 
immunopathogenesis of hepatitis C, and the prediction 
of the treatment response.
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INTRODUCTION
Hepatitis C virus (HCV) is a major cause of chronic 
viral hepatitis, liver cirrhosis, and hepatocellular 
carcinoma[1]. Chronic hepatitis C occurs in 60%-80% 
of individuals with acute HCV infection[2], liver cirrhosis 
arises in 20%-30% of individuals with chronic HCV 
infection, and hepatocellular carcinoma develops 
in 1%-4% of individuals with HCV-related liver 
cirrhosis[3]. HCV infection is, therefore, a leading cause 
of end-stage liver diseases throughout the world and 
the most common reason for liver transplantation in 
Western countries[4]. Although the characteristics of 
T lymphocyte and B lymphocyte responses against 
HCV have been revealed[2,5-8], natural killer (NK) cell 
responses are rather ill-defined and there are still many 
controversies to be resolved[9-14]. This review describes 
the current views on the role of NK cells in the defense 
against HCV infection, the relationship between NK cell 
responses and the immunopathogenesis of hepatitis 
C, the characteristics of NK cell responses in the 
coinfection of human immunodeficiency virus (HIV) 
and HCV, and the NK cell response as a predictor of 
treatment outcomes. 
HEPATITIS C VIRUS
HCV belongs to the Flaviviridae family and has a 
single-stranded, positive sense RNA genome that is 
approximately 9.6 kb in length. The RNA genome has 5’ 
and 3’ untranslated regions (UTRs). An open reading 
frame (ORF) is flanked by the UTRs and translated into 
a polyprotein via an internal ribosome entry site (IRES) 
in the 5’ UTR. The polyprotein is cleaved by host 
and viral proteases to yield three structural proteins 
(core, E1, and E2) and seven nonstructural proteins 
(p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B). 
The core proteins form a capsid that surrounds the 
HCV RNA genome. E1 and E2 are envelope proteins 
that comprise a viral envelope. The nonstructural 
proteins are not incorporated into the viral particles 
but play important roles in viral protein processing and 
genome replication. The NS3-4A complex is a serine 
protease that cleaves the polyprotein into individual 
nonstructural proteins. NS5B is a viral RNA-dependent 
RNA polymerase that duplicates HCV RNA genome. 
NS5A is a regulator of viral replication and virion 
assembly[15,16]. Newly developed direct acting antivirals 
(DAAs) inhibit HCV replication by targeting NS3-4A 
(telaprevir, boceprevir, simeprevir, asunaprevir, etc.), 
NS5B (sofosbuvir, dasabuvir, and others), or NS5A 
(ledipasvir, ombitasvir, daclatasvir, etc.)[16].
NATURAL KILLER CELLS
Since their identification in 1975[17,18], NK cells have 
been considered lymphocytes because they originate 
from the common lymphoid progenitor cell in the 
bone marrow. Unlike other lymphoid cells in adaptive 
immunity, such as T lymphocytes and B lymphocytes, 
NK cells lack antigen-specific cell surface receptors 
and do not require antigen presentation by antigen-
presenting cells or clonal expansion to initiate their 
effector functions[19]. 
NK cells participate in innate immunity to viruses[20,21] 
and tumors[22]. NK cells lyse virus-infected cells and 
tumor cells through degranulation of cytotoxic gra-
nules and the subsequent release of perforin and 
granzymes[23]. Another mechanism that NK cells 
utilize to exert cytotoxicity is the induction of target 
cell apoptosis through tumor necrosis factor-related 
apoptosis inducing ligand (TRAIL). In addition to their 
cytotoxic activity, NK cells are able to produce and 
secrete cytokines such as interferon (IFN)-γ and tumor 
necrosis factor (TNF)-α, which have antiviral activity[24]. 
The antiviral activity of NK cells is tightly regulated 
by interactions between NK cell surface receptors and 
their cognate ligands[25,26]. NK cells express a wide 
variety of inhibitory and activating receptors on the 
plasma membrane[27]. Killer cell immunoglobulin-like 
receptors (KIRs), natural killer group 2A (NKG2A), and 
killer cell lectin-like receptor subfamily G member 1 
(KLRG1) are examples of the inhibitory receptors, and 
NKG2D, NKG2C, and natural cytotoxicity receptors 
(NCRs), including NKp30, NKp44, and NKp46, are 
well-known activating receptors[19]. Normal nucleated 
cells express inhibitory ligands, such as class Ⅰ major 
histocompatibility complex (MHC) molecules, on 
their surfaces and inhibit NK cell activation through 
interactions between the MHC molecules and the KIRs. 
Normal cells do not express activating ligands such as 
major histocompatibility complex class I-related chain 
A/B (MICA/B) and UL16-binding proteins (ULBPs). 
In contrast, virus-infected cells may reduce the 
class Ⅰ MHC molecules and display activating ligands 
on their surfaces. NK cells that recognize the activating 
ligands become activated and exert their antiviral 
effector functions[19,27].
Human NK cells are CD3-CD56+ lymphocytes and 
are divided into two subsets based on the density of 
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CD56 expression on their surfaces[28]. Approximately 
10% of NK cells in the peripheral blood and nearly 
100% of NK cells in the secondary lymphoid tissues, 
such as the lymph nodes, have high surface expression 
of CD56 (CD56bright NK cells). The CD56bright subset can 
produce a large amount of cytokines and chemokines 
upon activation but has little or no ability to kill 
the target cells[29]. The majority of NK cells in the 
peripheral blood have relatively low surface expression 
of CD56 (CD56dim NK cells). The CD56dim subset has a 
reduced ability to produce cytokines, but some of them 
can spontaneously kill the susceptible target cells[22]. 
NK cells comprise 30%-50% of liver-resident 
lymphocytes[30,31], whereas 5%-15% of peripheral 
blood mononuclear cells (PBMCs) are NK cells. 
Hepatitis further increases the number of NK cells in 
the liver[32-34]. Chemokines secreted by Kupffer cells 
recruit NK cells to the liver, and cytokines secreted 
by the Kupffer cells, liver sinusoidal endothelial cells, 
and T cells promote the survival of the recruited NK 
cells[35]. Because of their enrichment in the liver and 
their ability to eliminate viral infections, NK cells may 
play key roles in the immune response against HCV 
infection[9,14,36].
INTERACTIONS BETWEEN HCV AND NK 
CELLS
The importance of NK cells in antiviral immune 
responses has promoted studies on the interactions 
between NK cells and HCV. Noninfectious HCV model 
systems, including recombinant HCV proteins, 
expression vectors encoding HCV proteins, and HCV 
replicon-containing hepatoma cell lines have been 
employed to investigate the interplay between NK 
cells and HCV[37-41]. The conclusions of the studies are, 
however, often contradictory[39-41], because the different 
experimental systems yield dissimilar results. Because 
there is still a lack of efficient small animal models for 
investigating the immunopathogenesis of hepatitis 
C[42,43], it is difficult to resolve the controversies over 
the functional status of NK cells in HCV infection. In 
2005, several research groups reported establishment 
of an HCV cell culture system[44-46], which produces 
infectious HCV virions. It provides researchers with 
an opportunity to simulate every step of the natural 
HCV life cycle in vitro. This revolutionary method 
has, therefore, encouraged in vitro studies on the 
interactions of NK cells with infectious HCV particles. 
Interaction of HCV proteins or virus particles with NK 
cells
The early studies that observed interactions between 
HCV and NK cells employed recombinant HCV 
proteins. Plate-bound E2 inhibits the effector functions 
of primary human NK cells by cross-linking CD81 on 
the surface of NK cells[37,38]. Cell-culture-generated 
HCV virions are also able to inhibit NK cells when they 
are bound to a plate[47]. Nevertheless, HCV virions do 
not impair the effector functions of NK cells, if they are 
soluble and mobile[47,48] (Figure 1, A). These results 
suggest that HCV E2 can induce cross-linking of CD81 
and inhibit NK cell function. However, this might be 
less likely in vivo, because CD81 cross-linking requires 
immobilization and a high concentration of cell-free 
HCV virions in the liver.
Interaction between HCV-infected cells and NK cells
Direct contact of NK cells with HCV-infected hepatoma 
cells reduces the functional capacity of the NK 
cells[49]. The activating receptors NKG2D and NKp30 
are downregulated on the surface of NK cells after 
cell-to-cell contact with the HCV-infected cells. 
Downregulation of the activating receptors results in 
the reduced functional capacity of the NK cells and the 
inhibition of the ex vivo NK cell functions[49,50] (Figure 
1, B). It appears that this phenomenon is associated 
with the NS3-4A protease activity in the infected cells, 
because inhibition of the NS3-4A protease eliminated 
contact-dependent suppression of NK cells by the HCV-
infected cells (unpublished data). The findings imply 
that HCV may impair the effector functions of NK cells 
in the infected liver. 
Interestingly, NK cells that are prestimulated with 
exogenous IFN-α can kill HCV-infected hepatoma 
cells[51,52]. This implies that the effect of innate 
cytokines, such as type Ⅰ IFNs including IFN-α and 
IFN-β, interleukin (IL)-8, IL-12, IL-15, and IL-18[12,53], 
should be considered when evaluating the interactions 
between NK cells and HCV-infected cells.
Role of accessory cells in the interplay between NK 
cells and HCV-infected cells
IFN-α and other innate cytokines secreted by 
accessory immune cells may modulate the interaction 
between NK cells and HCV-infected hepatocytes. 
The activation of NK cells by some pathogens indeed 
requires cytokines from accessory cells such as 
monocytes, macrophages, conventional dendritic cells 
(cDCs), and plasmacytoid dendritic cells (pDCs)[54-58]. 
In the liver, Kupffer cells can act as accessory cells that 
sense the viral RNA and indirectly activate NK cells by 
secreting innate cytokines[59,60]. 
Accessory cells regulate IFN-γ production by 
primary human NK cells after interacting with HCV-
infected hepatoma cells. In particular, the IFN-α 
produced by pDCs activates NK cells to produce 
IFN-γ[61]. This suggests that the IFN-α secreted by the 
accessory cells may overcome the inhibitory effect 
induced by direct contact between NK cells and HCV-
infected cells. Although HCV virions do not infect 
PBMCs[62], the interaction of pDCs with HCV-infected 
cells stimulates pDCs to secrete type Ⅰ IFNs[63-66], 
because the pDCs sense the HCV RNA in exosomes 
derived from the infected hepatoma cells[66] (Figure 
1, C). Therefore, close contact among HCV-infected 
hepatocytes, NK cells, and pDCs may simultaneously 
induce both inhibitory and activating signals, and 
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three distinct phases: the incubation phase, in which 
exposure to HCV occurs, but hepatitis and viremia are 
not yet detected; the acute phase, in which hepatitis 
and viremia are detected; and the chronic phase, 
which begins six months after the onset of the acute 
phase and is characterized by persistent HCV infection 
and chronic liver inflammation. The early phase of 
HCV infection generally refers to the period from the 
beginning of the incubation phase to the end of the 
acute phase[12]. 
NK cell activation in the early phase is influenced 
by the interactions between KIRs on NK cells and 
class Ⅰ MHC molecules, such as human leukocyte 
antigen (HLA)-A/B/C, on the HCV-infected cells. 
Genetic studies reveal that specific KIR and HLA-C 
pairs are associated with the spontaneous resolution of 
HCV infection[69,70], as host genetic factors, such as HLA 
genotypes, affect the T lymphocyte-related outcome 
of HCV infection[71]. NK cells from homozygous HLA-C 
group 1 (HLA-C1) individuals exert their effector 
functions more rapidly than those from homozygous 
HLA-C2 individuals[72]. This results from the reduced 
inhibition of NK cells by the KIR2DL3/HLA-C1 
interaction than that observed with other KIR/HLA 
the balance between the two signals may determine 
whether the NK cells are activated or inhibited. 
In addition, monocytes sense HCV replicon-
containing cells and secrete IL-18 which activates NK 
cells to produce IFN-γ[67] (Figure 1, D). Another study, 
however, reported somewhat different conclusions. 
The HCV NS5A protein stimulates monocytes 
through toll-like receptor (TLR)-4 and induces the 
secretion of IL-10, which is an immunosuppressive 
cytokine, while inhibiting the production of IL-12, 
which activates NK cells. IL-10 then stimulates the 
secretion of transforming growth factor (TGF)-β, which 
downregulates NKG2D on the NK cell surface, resulting 
in the subsequent functional impairment of the NK 
cells[68] (Figure 1, E). The discordance between the 
two studies may be due to the different experimental 
systems used. Further investigations are needed to 
clearly elucidate the role of accessory cells in the 
modulation of NK cells in HCV infection.
NK CELL RESPONSES IN THE EARLY 
PHASE OF HCV INFECTION
The natural course of HCV infection can be divided into 
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Figure 1  Interactions of natural killer cells with hepatitis C virus-infected hepatocytes and accessory cells. A: HCV virions may inhibit NK cells by cross-
linking of CD81 on the NK cells with the HCV E2 protein, if the HCV virions are immobilized and concentrated; B: Direct cell-to-cell contact of NK cells with HCV-
infected hepatoma cells reduces functional capacity of NK cells by downregulating the activating receptors NKG2D and NKp30; C: Exosomes harboring the HCV RNA 
are released from HCV-infected hepatoma cells and stimulate pDCs to secrete IFN-α which activates NK cells; D: The interaction with hepatoma cells containing 
HCV replicons stimulates monocytes to secrete IL-18 which activates NK cells; E: The HCV NS5A protein from HCV-infected hepatoma cells stimulates monocytes 
to secrete IL-10 and TGF-β which suppress NK cell function. HCV: Hepatitis C virus; NK cell: Natural killer cell; pDC: Plasmacytoid dendritic cell; IFN: Interferon; IL: 
Interleukin; TGF: Transforming growth factor; E2: Envelope 2 protein; NS5A: Nonstructural 5A protein. NKG2D: Natural killer group 2D.
Yoon JC et al . Natural killer cells in hepatitis C
interactions. NK cell cytotoxicity is increased only in 
individuals with KIRs that interact with HLA-C1 and is 
maximal in the spontaneously resolved cases[73]. The 
results suggest that NK cells are indeed important in 
the antiviral immune responses in the early phase of 
HCV infection. Therefore, it may be feasible that NK 
cell responses are not optimal in the acute phase of a 
substantial number of HCV infection cases, because 
60%-80% of individuals in the acute phase do not 
achieve spontaneous resolution and develop chronic 
hepatitis C[8].
Healthcare workers who have been accidentally 
exposed to HCV but do not develop acute hepatitis and 
viremia have strong NK cell responses against the very 
small amount of HCV in the incubation phase, which 
is within weeks after the exposure[74]. Increased NK 
cell degranulation in the early phase of HCV infection 
is also found in intravenous (IV) drug users who clear 
HCV spontaneously[75]. NK cells from individuals with 
spontaneous resolution show increased expression 
of the activating receptors, NKp46 and NKp44[74] 
and decreased expression of the inhibitory receptor 
NKG2A[75]. Moreover, increased NK cell cytotoxicity in 
the early phase is related to strong T cell responses 
in both healthcare workers and IV drug users[74,75]. 
Another study shows that NK cells from individuals 
who spontaneously eradicate HCV in the acute phase 
exhibit stronger IFN-γ secretion and express higher 
levels of NKG2D and NKp46 than NK cells from 
individuals who do not achieve spontaneous clearance 
of HCV infection[76]. These findings imply that sufficient 
and optimal NK cell responses in the early phase 
are associated with HCV clearance and prevent HCV 
infection from transitioning to the chronic phase. On 
the other hand, it is possible that individuals who do 
not spontaneously clear HCV and develop chronic 
hepatitis C cannot exert strong and optimal NK cell 
responses in the early phase. Weak and suboptimal 
activation of NK cells might be associated with the 
immune evasion strategies observed in the interactions 
of NK cells with HCV and accessory cells (Figure 1). 
NK CELL RESPONSES IN THE CHRONIC 
PHASE OF HCV INFECTION
Ex vivo studies using NK cells in PBMCs or intrahepatic 
lymphocytes from individuals with chronic hepatitis 
C have provided insights into the functional status of 
NK cells in chronic HCV infection. Although there are 
discrepancies in the ex vivo studies[34,68,77-80], it appears 
that the role of NK cells in the chronic phase of HCV 
infection is different from that in the early phase.
NK cells may be persistently activated in the chronic 
phase[77]. However, chronic activation of NK cells does 
not necessarily mean that all aspects of NK cell function 
are enhanced. NK cell cytotoxicity is increased, but 
IFN-γ production by the NK cells is reduced in chronic 
HCV infections[34,77]. This functional polarization of NK 
cells is due to the persistent exposure to endogenous 
IFN-α, which upregulates the expression of signal 
transducer and activator of transcription 1 (STAT1) in 
NK cells and induces preferential phosphorylation of 
STAT1 over STAT4. Phosphorylated STAT1 (pSTAT1) 
then stimulates NK cell cytotoxicity, while the lack of 
STAT4 phosphorylation impairs IFN-γ production, which 
is stimulated by phosphorylated STAT4[81-84].
It is reported that NKp46 expression is upregulated 
on peripheral blood NK cells and intrahepatic NK cells 
in chronic HCV infection[77]. NK cells with high surface 
expression of NKp46 (NKp46high NK cells) exert strong 
cytotoxicity and produce more IFN-γ. NKp46high NK cells 
are enriched in the inflamed liver and show enhanced 
cytolytic activity against HCV-infected hepatocytes and 
the hepatic stellate cells that are involved in hepatic 
fibrosis[85]. Another report reveals that NK cells induce 
the apoptosis of activated hepatic stellate cells[86]. 
These observations suggest that intrahepatic NK cells 
may control HCV replication and modulate hepatic 
fibrosis. However, intrahepatic NK cells also contribute 
to the immunopathology of chronic hepatitis C by 
inducing inflammation in the liver[87]. In contrast, other 
studies report that the increased numbers of NKp46+ 
NK cells in the peripheral blood are associated with the 
production of IL-10 which is an immunosuppressive 
cytokine. These results imply a lack of virus control 
rather than virus clearance in chronic hepatitis C[88]. 
Moreover, degranulation and TRAIL expression by 
intrahepatic NK cells are quite reduced in chronic HCV 
infection, even though NKp46 expression increases, 
suggesting that the NK cell response is impaired in 
the HCV-infected liver[89]. Thus, both defensive and 
pathogenic roles of NK cells should be considered 
together to properly interpret the NK cell response in 
the chronic phase of HCV infection (Table 1).
Other activating receptors, such as NKG2D, NKG2C, 
NKp30, and NKp44, may also be highly expressed on 
the surface of NK cells from individuals with a chronic 
HCV infection[34,77,88]. A noticeable number of studies 
describe, however, a reduction in the expression of the 
activating receptors NKG2D, NKp30 and NKp46[68,80] 
and an increase in the expression of the inhibitory 
receptors NKG2A and KLRG1[78-80,90] (Table 1). Although 
the reason for this significant controversy is unclear, it 
may be due to the differences in patient numbers and 
selection methods[9]. 
NK CELL RESPONSES IN THE 
COINFECTION OF HCV AND HIV
The importance of NK cell responses for HCV clearance is 
also observed in HCV/HIV coinfection. The spontaneous 
resolution of acute hepatitis C is associated with an 
effective IFN-γ-mediated NK cell response, which inhibits 
HCV replication, in HCV/HIV-coinfected patients[76]. 
However, preexisting HIV infection may hinder 
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NK cell responses against HCV infection[91,92]. HIV 
inhibits cDC activation, and this leads to the functional 
impairment of NK cells, because the crosstalk between 
activated cDCs and NK cells is important for the 
activation of the latter[21]. Therefore, the loss of cDC-NK 
cell interactions in HCV/HIV coinfection may result in 
defective NK cell responses to HCV[91]. In addition, NK 
cells are less sensitive to type Ⅰ IFNs secreted by pDCs 
during HIV infection. This reduced responsiveness may 
attenuate NK cells’ ability to control HCV infection, 
because type Ⅰ IFNs stimulate NK cell proliferation and 
cytotoxicity[21,91].
HCV/HIV coinfection results in an accelerated 
development of liver cirrhosis compared to HCV 
monoinfection. Because CD4+ T cells can stimulate NK 
cells to exert antifibrotic activity, the loss and functional 
impairment of CD4+ T cells by HIV may contribute to 
the faster progression to liver fibrosis[93]. 
NK CELLS AND THE TREATMENT 
RESPONSE
The treatment response to the pegylated IFN-α 
(PEG-IFN-α)/ribavirin combination therapy in chronic 
HCV infection is related to the patients’ KIR and 
HLA-C genotypes[94,95]. NK cells are important not 
only in spontaneous resolution in the early phase of 
infection but also in HCV clearance by IFN-α-based 
therapy in the chronic phase. In the latter, the injection 
of exogenous IFN-α activates NK cells to increase 
cytotoxicity[53,96]. 
The levels of NK cell activating receptors NKp30 
and NKp46 before PEG-IFN-α/ribavirin therapy may 
predict the treatment outcome[97]. In addition, higher 
IFN-α receptor (IFNAR) expression on the surface of 
CD16+CD56- NK cells before the combination therapy 
is associated with the treatment response[98]. 
Within hours of the first dose of IFN-α, the NK cells 
from the treated individuals are activated and express 
the NK cell activation marker CD69 and the activating 
receptors NKG2D and NKp30 on their surfaces. This 
phenomenon is more prominent in individuals who 
achieve early virological response[99]. Maximal NK cell 
cytotoxicity occurs at 24 h after treatment onset and 
is correlated with increased alanine aminotransferase 
in the serum, suggesting that the NK cells activated 
by exogenous IFN-α kill the HCV-infected cells in the 
liver. The functional polarization of NK cells observed 
in chronic HCV infection is intensified by IFN-α-based 
therapy[99] and mediated by STAT1 phosphorylation[81]. 
That is, both persistent exposure to endogenous IFN-α 
and acute exposure to large amount of exogenous 
recombinant IFN-α are able to induce preferential 
phosphorylation of STAT1 over STAT4 in intrahepatic 
NK cells.
NK cells from individuals with a rapid first-phase 
decrease in the HCV RNA level induce maximal STAT1 
phosphorylation, whereas NK cells from individuals 
with slow first-phase decrease in the HCV RNA 
level induce lower levels of STAT1 phosphorylation. 
Interestingly, the NK cells from the former persons 
become refractory to stimulation by IFN-α within 72 
h after the onset of the therapy. Therefore, the NK 
cell response in the first several days of PEG-IFN-α/
ribavirin therapy may be important for successful 
treatment[81].
The increase in activated CD69+ NK cells during 
IFN-α-based therapy predicts the rapid virological 
response. The sustained virological response (SVR) 
is associated with a higher NK perforin content and 
higher proportion of CD56dimCD16- NK cells. Indeed, 
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Table 1  Controversies over phenotype and function of natural killer cells in chronic hepatitis C virus infection
Phenotype/function Ref. reported increase Ref. reported decrease Ref. reported no change
Activation marker
   CD69 [34] [88]
Activating receptor
   NKG2D [34] [68]
   NKG2C [77]
   NKp46 [77,88,89] [80]
   NKp30 [88] [80]
   NKp44 [77]
Inhibitory receptor
KIR3DL1 [34]
   NKG2A [78-80]
   KLRG1 [90]
Cytotoxicity
   Degranulation [34,77] [68,80,89] [78]
   TRAIL expression [77] [89]
Immunostimulating cytokine 
   IFN-γ [78] [34,68] [77,88]
Immunosuppressive cytokine 
   IL-10 [88]
Yoon JC et al . Natural killer cells in hepatitis C
IL: Interleukin; IFN: Interferon; NKG2D: Natural killer group 2D; TRAIL: Factor-related apoptosis inducing ligand; KLRG1: Killer cell lectin-like receptor 
subfamily G member 1.
individuals achieving SVR exhibit higher NK cell 
cytotoxicity[100]. This implies that NK cell activation 
is required to achieve the early treatment response 
to HCV infection and that NK cell cytotoxicity is 
important to steadily suppress HCV replication in vivo. 
The NK cell response may be, therefore, used as a 
predictor of the treatment outcome for IFN-α-based 
therapy[12], and may supplement other predictors, such 
as the pretreatment level of interferon gamma-induced 
protein 10 (IP-10; CXCL10)[101,102] and the IL-28B (IFNL) 
genotype[103-106].
The IL-28B polymorphism is related to the altered 
expression of NK cell receptors, such as KIRs, NKG2A, 
and NKp30[106,107]. It is unclear, however, whether IL-
28B (IFN-λ) directly affect NK cell responses in HCV 
infection[108-111]. The IL-28B-favorable (CC) genotype is 
unassociated with favorable KIR/HLA-C haplotypes[95]. 
Therefore, it would be better to utilize the NK cell 
response in hepatitis C as an additive predictor of the 
IFN-based treatment outcome.
It appears that TRAIL expression is also increased 
in NK cells from individuals achieving SVR after PEG-
IFN-α/ribavirin treatment, suggesting that the NK 
cells activated by IFN-α kill the HCV-infected cells by 
employing not only perforin and granzymes but also 
TRAIL[52].
In HCV/HIV coinfection, the baseline frequency 
of the CD56-CD16+ NK cell subset, which is highly 
dysfunctional, is negatively correlated with response to 
IFN-α-based treatment[112].
Several DAAs, such as NS3-4A protease inhibitors, 
NS5B polymerase inhibitors, and NS5A inhibitors, have 
been developed to treat chronic hepatitis C. Highly 
efficient combinations of these DAAs allow IFN-free 
regimens[16]. Unlike IFN-α-based therapy, the clearance 
of HCV by the NS5A inhibitor (daclatasvir)/NS3-4A 
protease inhibitor (asunaprevir) combination therapy 
leads to the loss of intrahepatic immune activation by 
IFN-α and the normalization of functionally polarized 
intrahepatic NK cells[113]. Therefore, the restoration of 
the NK cells’ ability to produce IFN-γ during IFN-free 
DAA therapy may indicate the treatment response. 
PROBLEMS TO BE SOLVED IN RESEARCH 
ON NK CELLS IN HCV INFECTION
The lack of small animal models has greatly hampered 
research on the role of NK cells in hepatitis C. Although 
it supports the entire life cycle of HCV[114,115], the 
chimpanzee model is not readily available because 
of high costs and ethical concerns[42]. In vitro models 
and human ex vivo models are, therefore, the best 
currently available HCV model systems. These models 
have, however, several drawbacks.
In vitro infection of human hepatoma cell lines with 
cell-culture-generated HCV supports high-level HCV 
replication, but it cannot precisely mimic the natural 
HCV infection in normal hepatocytes. Moreover, in 
vitro HCV infection is supported by a limited number 
of Huh7-derived human hepatoma cell lines[44-46]. 
Although cultured primary human hepatocytes can 
be infected with cell-culture-generated HCV in vitro, 
they support only low levels of HCV replication, which 
requires the detection of the negative strand viral RNA 
by polymerase chain reaction (PCR)[116]. In terms of NK 
cell research, the major drawback of the in vitro HCV 
infection model is that both hepatoma cell lines and 
primary hepatocytes in a cell culture dish or a plate are 
unable to precisely reproduce the organization of the 
immune environment in the liver and in the adjacent 
lymph nodes.
Because T lymphocytes have antigen specificity, 
HCV-specific T cells are easily distinguished from 
other T cells ex vivo. However, NK cells do not possess 
antigen specificity[19]. It is, therefore, uncertain 
whether the majority of peripheral blood NK cells 
tested ex vivo have really interacted with the HCV-
infected hepatocytes or HCV virions in vivo. The use 
of intrahepatic NK cells does not necessarily ensure 
that the NK cells have directly contacted HCV-infected 
hepatocytes, because the proportion of infected 
hepatocytes in the liver of individuals with chronic HCV 
infection could be as low as 1% and the infected cells 
only occur in clusters throughout the liver[117].
NK cells that actively exerted their effector functions 
on HCV in vivo and thereby have no remaining effector 
capacity may appear as functionally impaired cells ex 
vivo. In contrast, NK cells that could not exert any 
effector functions against HCV infection in vivo and 
thereby retain their effector capacity may appear as 
functionally competent cells ex vivo. Therefore, our ex 
vivo observations may not accurately reflect the real 
role and functional status of the NK cells in the HCV-
infected liver.
Indeed, in vitro studies and human ex vivo studies 
have frequently produced contradictory results. 
Thus, advances in the experimental methods in the 
field of HCV research, such as the development of 
a genetically humanized, immunocompetent mouse 
model[118,119], are required to obtain clearer insights 
into the functional status of NK cells in HCV infection. 
Currently, a balanced interpretation of the results from 
various papers is needed to appropriately understand 
the role of NK cells in each phase of HCV infection.
CONCLUSION
While T cell responses are critical for adaptive 
immunity to HCV, NK cells are crucial players in innate 
immunity to HCV. In the early phase of HCV infection, 
the enhanced functional capacity of NK cells is corre-
lated with spontaneous resolution and strong T cell 
responses. It appears that NK cells play an important 
role in preventing the conversion of the early phase 
of HCV infection to the chronic phase. The various 
strategies that are employed by HCV to evade NK cell 
responses may interfere with the protective functions 
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of NK cells in the early phase and might contribute to 
the progression to chronic hepatitis C, which develops 
in about three fourths of individuals with an acute 
HCV infection. In the chronic phase, it appears that 
NK cells are important for controlling HCV replication 
and the resistance to hepatic fibrosis. A considerable 
number of studies, however, refute this possibility 
by showing that the NK cells’ function is impaired in 
chronic HCV infection. The NK cell response is also 
associated with the treatment response. Increased 
NK cell effector functions during IFN-α-based therapy 
may predict the treatment outcome. Although there 
has been significant progress in the research on NK 
cells in hepatitis C, physiological models, such as an 
immunocompetent mouse model, must be established 
to solve the problems of the current experimental 
methods and settle the controversies over the role 
and functional status of NK cells in each phase of HCV 
infection.
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